论文部分内容阅读
目的探讨丹参酮ⅡA磺酸钠对慢性肺源性心脏病(肺心病)急性加重期血栓前状态及肺动脉高压的影响。方法将56例慢性肺心病急性加重期患者随机分为两组,治疗组3 l例,常规组25例,另选同期健康成人26例为健康对照组,常规组予以常规抗感染、平喘、扩管利尿、吸氧等常规治疗,治疗组在此基础上给予丹参酮ⅡA磺酸钠40 mg/d静滴14 d。观察两组患者治疗前、后测定全血黏度、纤维蛋白原、D-二聚体、肺动脉收缩压。结果肺心病患者全血低切黏度、纤维蛋白原、D-二聚体及肺动脉收缩压与对照组比较差异均有统计学意义(P<0.05)。治疗组患者治疗后全血黏度、纤维蛋白原、D-二聚体、肺动脉收缩压显著降低(P<0.05),常规组治疗前、后各指标差异无统计学意义(P>0.05)。结论丹参酮ⅡA磺酸钠可明显抑制肺心病急性加重期的血栓前状态、降低肺动脉压。
Objective To investigate the effect of tanshinone Ⅱ A sulfonate on prothrombotic state and pulmonary hypertension in patients with chronic cor pulmonale (pulmonary heart disease) during acute exacerbation. Methods Fifty-six patients with acute exacerbation of chronic pulmonary heart disease were randomly divided into two groups: treatment group (31 cases), conventional therapy group (25 cases), and healthy control group (26 cases) as normal control group Expansion tube diuretic, oxygen and other conventional treatment, the treatment group on the basis of tanshinone Ⅱ A sulfonate 40 mg / d intravenous 14 d. Whole blood viscosity, fibrinogen, D-dimer and pulmonary artery systolic pressure were measured before and after treatment. Results Low blood viscosity, fibrinogen, D-dimer and pulmonary artery systolic blood pressure in patients with pulmonary heart disease were significantly lower than those in the control group (P <0.05). After treatment, the whole blood viscosity, fibrinogen, D-dimer and pulmonary artery systolic pressure were significantly decreased in the treatment group (P <0.05). There was no significant difference between the two groups before and after treatment (P> 0.05). Conclusion Sodium tanshinone Ⅱ A sulfonate can obviously inhibit the prothrombotic state of pulmonary heart disease during acute exacerbation and decrease pulmonary arterial pressure.